Aridis Pharmaceuticals announced that the Cystic Fibrosis Foundation has more than doubled its research agreement for the clinical development of AR-501 from $2.9M to up to $7.5M. Aridis also announced that the U.S. Food and Drug Administration has granted both Fast-Track Designation and Qualified Infectious Disease Product Designation for AR-501. Additionally, the FDA cleared AR-501’s Investigational New Drug Application and the company intends to initiate the Phase 1/2a clinical trial next month.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.